IPO - Acurx Pharmaceuticals, Inc.

Form Type: S-1

Filing Date: 2025-07-15

Corporate Action: Ipo

Type: New

Accession Number: 000110465925067841

Filing Summary: Acurx Pharmaceuticals, Inc. has filed an S-1 Registration Statement with the SEC for an initial public offering (IPO) of up to 9,157,596 shares of its common stock. The offering includes shares that may be issued upon the exercise of warrants, namely series G-1 warrants and series G-2 warrants, with exercise prices of $0.425 and $0.75 per share, respectively. Acurx is focused on developing a new class of antibiotics targeting difficult-to-treat bacterial infections, with a particular emphasis on antibiotic candidates that inhibit the growth of Gram-positive bacteria, which are recognized as significant healthcare concerns by WHO and CDC. The prospectus outlines potential risks associated with investing in the company's stock and indicates that they are classified as an emerging growth company, which allows them to utilize reduced reporting requirements. Additionally, the document references prior financial transactions, including a May 2025 agreement with Lincoln Park Capital Fund, LLC for a potential sale of common stock amounting to $12 million. It notes that the proposed offering is subject to SECon approval, and the common stock is scheduled to commence being sold after the effective date of the registration statement, with Acurx not being responsible for any proceeds from the sale of shares by selling stockholders. The summary also highlights the speculative nature of the investment and the risks applicable for potential investors to consider.

Form Type: CORRESP

Filing Date: 2025-05-27

Corporate Action: Ipo

Type: New

Accession Number: 000110465925052966

Filing Summary: Acurx Pharmaceuticals, Inc. is requesting the acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-287478). The company seeks the registration to become effective at 4:01 p.m. on May 29, 2025, or as soon thereafter as practicable. The request is made pursuant to Rule 461 of Regulation C under the Securities Act of 1933. The letter is signed by David P. Luci, President and Chief Executive Officer of the company.

Form Type: S-1

Filing Date: 2025-05-21

Corporate Action: Ipo

Type: New

Accession Number: 000110465925051615

Filing Summary: Acurx Pharmaceuticals, Inc. filed a registration statement under the Securities Act of 1933 on May 21, 2025. This S-1 form relates to the resale of up to 10,899,258 shares of common stock owned by Lincoln Park Capital Fund, LLC. The shares are being offered for resale as part of a Purchase Agreement signed on May 8, 2025, where Lincoln Park committed to purchasing up to $12 million of Acurx's common stock over the term of the agreement. The prospectus outlines that Acurx will not receive any proceeds from the sale of these shares, which will be sold depending on market conditions. The company also confirmed its status as an emerging growth company and smaller reporting company, which will affect its reporting obligations. Key risks and considerations for investors include potential dilution of shares as a result of sales to Lincoln Park and other market risks associated with the offering. The last reported sale price of Acurx's common stock on May 20, 2025, was $0.42 per share, and the stock is traded on the Nasdaq under the symbol 'ACXP'.

Form Type: S-1

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000110465925032184

Filing Summary: Acurx Pharmaceuticals, Inc. filed a registration statement on Form S-1 with the SEC to offer up to 8,399,700 shares of its common stock. The offering includes shares issuable upon the exercise of series F warrants and placement agent warrants. The estimated effective date for this offering is not specified, but sales are expected to commence soon after the effective date. The company is classified as an 'emerging growth company' and a 'smaller reporting company', with a focus on developing antibiotics for difficult-to-treat infections. The shares will be sold by certain stockholders, with proceeds from sales going entirely to them, while Acurx will not receive any proceeds from the resale but may receive proceeds from warrant exercises. The registration includes discussions of the risks involved with investing in the company's securities, including ongoing compliance with Nasdaq listing requirements. Recent developments highlight upcoming compliance deadlines and offerings that occurred in early 2025.

Form Type: CORRESP

Filing Date: 2025-02-04

Corporate Action: Ipo

Type: New

Accession Number: 000110465925009147

Filing Summary: Acurx Pharmaceuticals, Inc. is requesting the U.S. Securities and Exchange Commission for acceleration of the effective date of its Registration Statement on Form S-1, which is designated as File No. 333-284627. The company seeks to have the registration become effective on February 6, 2025, at 4:01 p.m. (Washington, D.C. time), or as soon thereafter as practicable. This request is made in accordance with Rule 461 of Regulation C under the Securities Act of 1933, as amended. The correspondence indicates the involvement of legal counsel from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., and provides contact details for further inquiries.

Form Type: S-1

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000141057825000067

Filing Summary: Acurx Pharmaceuticals, Inc. filed Form S-1 registration statement with the SEC for the proposed public offering of 2,610,841 shares of common stock. This includes 2,463,058 shares issuable upon exercise of series E warrants at an exercise price of $0.90 per share and 147,783 shares issuable upon exercise of placement agent warrants with an exercise price of $1.2688 per share. The selling stockholders will receive proceeds from these sales, while Acurx will incur expenses related to the offering. The common stock is listed on The Nasdaq Capital Market under the symbol 'ACXP.' The last reported price of the stock was $0.759 per share on January 30, 2025. Acurx is classified as an emerging growth company and is subject to reduced public reporting requirements. Risks associated with the offering are discussed in the prospectus, indicating that investing in the company's stock is speculative and entails significant risk.